These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 16522729

  • 1. Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice.
    Jensen LJ, Denner L, Schrijvers BF, Tilton RG, Rasch R, Flyvbjerg A.
    J Endocrinol; 2006 Mar; 188(3):493-501. PubMed ID: 16522729
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.
    Schrijvers BF, De Vriese AS, Tilton RG, Van de Voorde J, Denner L, Lameire NH, Flyvbjerg A.
    Horm Metab Res; 2005 Jan; 37(1):21-5. PubMed ID: 15702434
    [Abstract] [Full Text] [Related]

  • 3. Gene expression of receptor for advanced glycosylation end products and its modulation by aminoguanidine in diabetic kidney tissue.
    Huang Y, Lin S, Zhou J.
    Chin Med J (Engl); 1998 Aug; 111(8):698-704. PubMed ID: 11245022
    [Abstract] [Full Text] [Related]

  • 4. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice.
    Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, Rasch R.
    Diabetes; 2004 Jan; 53(1):166-72. PubMed ID: 14693711
    [Abstract] [Full Text] [Related]

  • 5. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody.
    Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R.
    Diabetes; 2002 Oct; 51(10):3090-4. PubMed ID: 12351452
    [Abstract] [Full Text] [Related]

  • 6. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model.
    Meier M, Park JK, Overheu D, Kirsch T, Lindschau C, Gueler F, Leitges M, Menne J, Haller H.
    Diabetes; 2007 Feb; 56(2):346-54. PubMed ID: 17259378
    [Abstract] [Full Text] [Related]

  • 7. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
    Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH.
    Chin Med J (Engl); 2006 May 20; 119(10):814-21. PubMed ID: 16732983
    [Abstract] [Full Text] [Related]

  • 8. Oral administration of grape seed proanthocyanidin extracts downregulate RAGE dependant nuclear factor- kappa BP65 expression in the hippocampus of streptozotocin induced diabetic rats.
    Xu L, Li B, Cheng M, Zhang W, Pan J, Zhang C, Gao H.
    Exp Clin Endocrinol Diabetes; 2008 Apr 20; 116(4):215-24. PubMed ID: 18273752
    [Abstract] [Full Text] [Related]

  • 9. The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription.
    Liu IM, Tzeng TF, Liou SS, Chang CJ.
    J Ethnopharmacol; 2009 Jul 15; 124(2):211-8. PubMed ID: 19397971
    [Abstract] [Full Text] [Related]

  • 10. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation.
    Usui HK, Shikata K, Sasaki M, Okada S, Matsuda M, Shikata Y, Ogawa D, Kido Y, Nagase R, Yozai K, Ohga S, Tone A, Wada J, Takeya M, Horiuchi S, Kodama T, Makino H.
    Diabetes; 2007 Feb 15; 56(2):363-72. PubMed ID: 17259380
    [Abstract] [Full Text] [Related]

  • 11. Renal prostaglandin E2 receptor (EP) expression profile is altered in streptozotocin and B6-Ins2Akita type I diabetic mice.
    Nasrallah R, Xiong H, Hébert RL.
    Am J Physiol Renal Physiol; 2007 Jan 15; 292(1):F278-84. PubMed ID: 16954344
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
    Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP.
    Invest Ophthalmol Vis Sci; 2007 Feb 15; 48(2):858-65. PubMed ID: 17251488
    [Abstract] [Full Text] [Related]

  • 13. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice.
    Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H.
    J Clin Invest; 2001 Jul 15; 108(2):261-8. PubMed ID: 11457879
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes.
    Schrijvers BF, De Vriese AS, Van de Voorde J, Rasch R, Lameire NH, Flyvbjerg A.
    Nephrol Dial Transplant; 2004 May 15; 19(5):1092-7. PubMed ID: 14993490
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin.
    Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto H.
    Diabetes; 2006 Sep 15; 55(9):2510-22. PubMed ID: 16936199
    [Abstract] [Full Text] [Related]

  • 20. Role of kidney ADP-ribosyl cyclase in diabetic nephropathy.
    Kim SY, Park KH, Gul R, Jang KY, Kim UH.
    Am J Physiol Renal Physiol; 2009 Feb 15; 296(2):F291-7. PubMed ID: 19073639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.